-
1.发明申请公开(公告)号：US20180250285A1
公开(公告)日：2018-09-06
申请号：US15974112
申请日：2018-05-08
申请人： Michael HAYDEN
发明人： Michael HAYDEN
IPC分类号： A61K31/4704 , B65D81/32 , A61K31/451
CPC分类号： A61K31/4704 , A61K31/451 , A61K2300/00 , B65D81/32
摘要： This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder, e.g., HD.
-
2.发明申请公开(公告)号：US20180133209A1
公开(公告)日：2018-05-17
申请号：US15801703
申请日：2017-11-02
申请人： Michael HAYDEN
发明人： Michael HAYDEN
IPC分类号： A61K31/4704 , B65D81/32 , A61K31/451
CPC分类号： A61K31/4704 , A61K31/451 , A61K2300/00 , B65D81/32
摘要： This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder, e.g., HD.
-
公开(公告)号：US20180002753A1
公开(公告)日：2018-01-04
申请号：US15410091
申请日：2017-01-19
申请人： Amir TCHELET , Michael HAYDEN , Liat HAYARDENY , Colin James Douglas ROSS , Iris GROSSMAN , David LADKANI
发明人： Amir TCHELET , Michael HAYDEN , Liat HAYARDENY , Colin James Douglas ROSS , Iris GROSSMAN , David LADKANI
CPC分类号： C12Q1/6883 , A61K38/02 , A61K38/16 , C12Q2600/106 , C12Q2600/156
摘要： The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of Group 2, one or more C alleles at the location of Group 3, one or more G alleles at the location of Group 4, or one or more T alleles at the location of kgp18432055, kgp279772, kgp3991733 or kgp7242489; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
-
4.发明申请公开(公告)号：US20170319569A1
公开(公告)日：2017-11-09
申请号：US15655580
申请日：2017-07-20
申请人： Michael HAYDEN
发明人： Michael HAYDEN
IPC分类号： A61K31/4704 , A61K31/451 , B65D81/32
CPC分类号： A61K31/4704 , A61K31/451 , A61K2300/00 , B65D81/32
摘要： This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder, e.g., HD.
-
5.发明申请公开(公告)号：US20190117639A1
公开(公告)日：2019-04-25
申请号：US16223993
申请日：2018-12-18
申请人： Michael HAYDEN
发明人： Michael HAYDEN
IPC分类号： A61K31/4704 , B65D81/32 , A61K31/451
摘要： This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder, e.g., HD.
-
6.发明申请公开(公告)号：US20170105996A1
公开(公告)日：2017-04-20
申请号：US15294075
申请日：2016-10-14
CPC分类号： A61K31/52 , A61K9/0053 , A61K9/20 , A61K9/2846 , A61K45/06 , A61P1/16 , A61K2300/00
摘要： Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering front type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
-
公开(公告)号：US20150110733A1
公开(公告)日：2015-04-23
申请号：US14520280
申请日：2014-10-21
申请人： Amir TCHELET , Michael HAYDEN , Liat HAYARDENY , Colin James Douglas ROSS , Iris GROSSMAN , David LADKANI
发明人： Amir TCHELET , Michael HAYDEN , Liat HAYARDENY , Colin James Douglas ROSS , Iris GROSSMAN , David LADKANI
CPC分类号： C12Q1/6883 , A61K38/02 , A61K38/16 , C12Q2600/106 , C12Q2600/156
摘要： The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of Group 2, one or more C alleles at the location of Group 3, one or more G alleles at the location of Group 4, or one or more T alleles at the location of kgp18432055, kgp279772, kgp3991733 or kgp7242489; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
摘要翻译： 本发明提供了一种治疗患有多发性硬化的人类受试者或与多发性硬化一致的单一临床攻击的方法，所述药物组合物包含乙酸格拉默和药学上可接受的载体，包括以下步骤：（i）确定 受试者在对应于选自以下的一个或多个单核苷酸多态性（SNP）的位置的位置：组1，（ii）如果受试者的基因型含有一个或多个，则将该受试者鉴定为乙酸格拉默的预测应答者 在组2的位置上更多的A等位基因，在组3的位置处的一个或多个C等位基因，在组4的位置的一个或多个G等位基因，或位于kgp18432055，kgp279772，kgp3991733或 kgp7242489; 和（iii）仅当受试者被鉴定为乙酸格拉默的预测应答者时，向受试者施用包含乙酸格拉默和药学上可接受的载体的药物组合物。
-
8.发明申请COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE, AND INFLAMMATORY DISEASES 审中-公开用于治疗血管，自身免疫和炎症疾病的组合物和方法公开(公告)号：US20110269755A1
公开(公告)日：2011-11-03
申请号：US12964722
申请日：2010-12-09
申请人： Michael HAYDEN , Noel Hall
发明人： Michael HAYDEN , Noel Hall
IPC分类号： A61K31/5377 , A61K31/351 , A61K31/40 , A61P1/16 , A61K31/405 , A61P3/06 , A61P9/10 , A61P3/10 , A61K31/343 , A61K31/505
CPC分类号： A61K45/06 , A61K9/2004 , A61K31/00 , A61K31/365 , A61L31/16 , A61L2300/432 , C07D307/88 , A61K2300/00
摘要： The disclosure provides compositions and methods for the treatment of vascular, autoimmune, and inflammatory diseases using a combination of an inosine monophosphate dehydrogenase (IMPDH) inhibitor and a HMG CoA reductase inhibitor.
摘要翻译： 本公开提供了使用肌苷一磷酸脱氢酶（IMPDH）抑制剂和HMG CoA还原酶抑制剂的组合来治疗血管，自身免疫和炎性疾病的组合物和方法。
-
9.发明申请公开(公告)号：US20180369228A1
公开(公告)日：2018-12-27
申请号：US16117604
申请日：2018-08-30
申请人： Michael HAYDEN
发明人： Michael HAYDEN
IPC分类号： A61K31/4704 , B65D81/32 , A61K31/451
摘要： This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder, e.g., HD.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.024 秒)
